Corbus Pharmaceuticals Holdings (FRA:3371) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3371 Corbus Pharmaceuticals Holdings Inc FRA:3371
35 GF Score
Price €7.90
GF Value €0.91
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Corbus Pharmaceuticals Holdings Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:3371
35GF Score
Corbus Pharmaceuticals Holdings Inc FRA:3371
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corbus Pharmaceuticals Holdings (FRA:3371) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of €7.90 is trading 768.1% above its estimated GF Value™ of €0.91. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for FRA:3371:

  • Short Ratio:
  • GF Value™: €0.91 vs. price of €7.90 (768.1% above fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the FRA:3371 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
35GF Score

Get the complete analysis for FRA:3371

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€0.91
GF Value